Oak Hill Bio Holdings
Latest round
- Series A
Last raised
- Jun 2026
Total raised
- $33M
Investors
- 4
About Oak Hill Bio Holdings
Based in the UK, Oak Hill Bio Holdings Ltd.Founded in 2021, Oak Hill Bio Holdings Ltd. operates out of Altrincham, UK. The company focuses on developing therapies for rare diseases, specifically targeting treatments that have been deprioritized by larger firms.Oak Hill Bio Holdings specializes in the acquisition and development of late-stage rare disease therapeutics that have been deprioritized by larger pharmaceutical companies. Their primary product offerings include rugonersen (OHB-724), an antisense oligonucleotide designed to target Angelman syndrome, and mecasermin rinfabate (OHB-607), a recombinant human IGF-1/IGFBP-3 therapy aimed at addressing complications related to extremely premature birth. These products primarily serve the pediatric population afflicted by these rare conditions, providing crucial therapeutic interventions where limited options currently exist.The revenue model for Oak Hill Bio Holdings is predicated on partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies, facilitating the development and commercialization of its therapeutic candidates. Transactions generally involve structured agreements where the company may receive upfront payments, milestone payments tied to development progress, and royalties on future sales. The firm’s flagship products, rugonersen and mecasermin rinfabate, are central to these revenue-generating activities, with their success in clinical trials potentially leading to lucrative licensing deals or sales agreements.In June 2026, Oak Hill Bio Holdings Ltd. The company aims to expand its portfolio by launching new products that address rare diseases, with specific timelines for product rollouts yet to be disclosed. Additionally, Oak Hill Bio plans to broaden its market presence into new geographic regions, focusing on areas with high unmet medical need. This strategic approach is designed to maximize the therapeutic impact of its current offerings and enhance the overall market reach of the company.
Who invested in Oak Hill Bio Holdings
4 investors across 1 round
See all investors in Oak Hill Bio Holdings
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 1, 2026
Amount
$33M
Investors
Questions about Oak Hill Bio Holdings
Who invested in Oak Hill Bio Holdings?
Oak Hill Bio Holdings has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oak Hill Bio Holdings raised?
Oak Hill Bio Holdings has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Oak Hill Bio Holdings last raise money?
Oak Hill Bio Holdings's most recent round on record is a Series A, in Jun 2026.
What does Oak Hill Bio Holdings do?
Based in the UK, Oak Hill Bio Holdings Ltd.
Where is Oak Hill Bio Holdings headquartered?
Oak Hill Bio Holdings is headquartered in Altrincham, UK.
Which VCs invest in companies like Oak Hill Bio Holdings?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Oak Hill Bio Holdings's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Oak Hill Bio Holdings? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.